528 related articles for article (PubMed ID: 24051027)
41. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
42. Taraxacum mongolicum extract exhibits a protective effect on hepatocytes and an antiviral effect against hepatitis B virus in animal and human cells.
Jia YY; Guan RF; Wu YH; Yu XP; Lin WY; Zhang YY; Liu T; Zhao J; Shi SY; Zhao Y
Mol Med Rep; 2014 Apr; 9(4):1381-7. PubMed ID: 24481875
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
[TBL] [Abstract][Full Text] [Related]
44. [Studies on the effects of tea catechins against hepatitis B virus infection].
Li J; Zhou L; Zhang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Nov; 35(6):404-7. PubMed ID: 11840771
[TBL] [Abstract][Full Text] [Related]
45. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
[TBL] [Abstract][Full Text] [Related]
46. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.
Guner R; Karahocagil M; Buyukberber M; Kandemir O; Ural O; Usluer G; Inan D; Koksal I; Baykam N; Hizel K; Yamazhan T; Esen S; Tasyaran MA
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1185-91. PubMed ID: 21934508
[TBL] [Abstract][Full Text] [Related]
47. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
49. [Effect of ampelopsis of Ampelopsis grossedentata on duck hepatitis B virus].
Yan L; Zheng Z
Zhongguo Zhong Yao Za Zhi; 2009 Apr; 34(7):908-10. PubMed ID: 19623994
[TBL] [Abstract][Full Text] [Related]
50. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro.
Xu J; Wang J; Deng F; Hu Z; Wang H
Antiviral Res; 2008 Jun; 78(3):242-9. PubMed ID: 18313149
[TBL] [Abstract][Full Text] [Related]
51. [Inhibiting effects of root of Mallotus apelta on duck hepatitis B virus].
Xu S; Lü ZP; Cai HB; Zhang XG; Liu Q; Tan Y
Zhong Xi Yi Jie He Xue Bao; 2006 May; 4(3):285-8. PubMed ID: 16696917
[TBL] [Abstract][Full Text] [Related]
52. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
53. In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik.
Wu LL; Yang XB; Huang ZM; Liu HZ; Wu GX
Acta Pharmacol Sin; 2007 Mar; 28(3):404-9. PubMed ID: 17303004
[TBL] [Abstract][Full Text] [Related]
54. Chemical constituents of Swertia yunnanensis and their anti-hepatitis B virus activity.
Cao TW; Geng CA; Jiang FQ; Ma YB; He K; Zhou NJ; Zhang XM; Zhou J; Chen JJ
Fitoterapia; 2013 Sep; 89():175-82. PubMed ID: 23747320
[TBL] [Abstract][Full Text] [Related]
55. Henrylactones A-E and anti-HBV constituents from Illicium henryi.
Liu JF; Jiang ZY; Zhang Q; Shi Y; Ma YB; Xie MJ; Zhang XM; Chen JJ
Planta Med; 2010 Feb; 76(2):152-8. PubMed ID: 19670158
[TBL] [Abstract][Full Text] [Related]
56. [Experimental study on effect of Shenling Yigan Granule in antagonizing duck hepatitis B virus].
Zhang HQ; Ge H; Li X
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Mar; 27(3):244-6. PubMed ID: 17432688
[TBL] [Abstract][Full Text] [Related]
57. Anti-hepatitis B virus effects of the traditional Chinese herb Artemisia capillaris and its active enynes.
Geng CA; Yang TH; Huang XY; Yang J; Ma YB; Li TZ; Zhang XM; Chen JJ
J Ethnopharmacol; 2018 Oct; 224():283-289. PubMed ID: 29890315
[TBL] [Abstract][Full Text] [Related]
58. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
Tsiquaye KN; Slomka MJ; Maung M
J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
[TBL] [Abstract][Full Text] [Related]
59. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
Schorr O; Borel C; Trepo C; Zoulim F; Hantz O
J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387
[TBL] [Abstract][Full Text] [Related]
60. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
Aguesse-Germon S; Liu SH; Chevallier M; Pichoud C; Jamard C; Borel C; Chu CK; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 1998 Feb; 42(2):369-76. PubMed ID: 9527788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
